Sonova Holding AG reported a 17.3% increase in normalized EBITDA to $794 million for fiscal year 2025-26, with the margin improving 240 basis points in local currencies to 23.7%. Total segment sales rose 7.5% to $3.4 billion, driven by a 9.5% increase in wholesale revenues to $1.9 billion and a 5.1% rise in retail revenue to $1.5 billion. Cochlear implant sales reached $252 million, down 11% overall, or 3.8% lower excluding China, amid competitive pressure and the introduction of VDP in China. Exchange rate developments negatively impacted normalized EBITDA by CHF130 million, reducing the margin by 1.5 percentage points. The company proposed a 7% dividend increase to 4.70 per share and issued an outlook for fiscal 2026-27 of 5% to 8% consolidated sales growth and 7% to 10% core EBIT growth at constant exchange rates.
Sonova H AgSonova reported a 17.3% rise in normalized EBITDA and improved margins, with a positive outlook for 2026-27.